MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
South San Francisco, US
61 (est)

Key People at MyoKardia

Neil Kumar

Neil Kumar

Interim Vice President of Business Development
Charles Homcy

Charles Homcy

Interim CEO and Board Member

MyoKardia Locations

South San Francisco, US

MyoKardia Metrics

MyoKardia Summary

Market capitalization

$435 M

Closing share price


MyoKardia Market Value History

MyoKardia Company Life